Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2012 Jan 28;12(2):132–137. doi: 10.1016/j.clml.2011.12.005

Table 3.

Treatment Regimens Delivered

Treatment Total N = 66 Unmutated IGHV Sequence N = 50 Mutated IGHV Sequence N = 16
Received Treatment 50 (76%) 41 (82%) 9 (56%)
Treatment Base
    Rituximab 49 (74%) 40 (80%) 9 (56%)
    Ofatumumab 3 (5%) 2 (4%) 1 (6%)
    Alemtuzumab 11 (17%) 10 (20%) 1 (6%)
    Anthracycline 12 (18%) 9 (18%) 3 (19%)
    Bendamustine 18 (27%) 16 (32%) 2 (11%)
    Pentostatin 6 (9%) 4 (8%) 2 (11%)
    Fludarabine 14 (21%) 11 (22%) 3 (19%)
    Alkylator 8 (12%) 6 (12%) 2 (11%)
    mTor inhibitors/IMIDs 5 (8%) 4 (8%) 1 (6%)
    Allogeneic BMT 11 (17%) 11 (22%) 0 (0%)
    Other 3 (5%) 2 (4%) 1 (6%)

Abbreviations: IGHV = immunoglobulin heavy-chain variable; IMIDs = immunomodulatory drugs.